- Published on
Medicine – Laboratory Findings in Coagulation Disorders
Coagulation investigations help distinguish disorders of coagulation factors, platelet function, anticoagulant effects and disseminated intravascular coagulation (DIC).
The principal screening investigations include prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT) and platelet count. Bleeding time (BT) is included for traditional examination purposes, although it is now rarely used in clinical practice.
PT assesses the extrinsic and common coagulation pathways, aPTT assesses the intrinsic and common pathways, and TT assesses conversion of fibrinogen to fibrin. Platelet count and platelet function investigations evaluate primary haemostasis.
1. Laboratory Findings in Coagulation Disorders
Abbreviations: N = normal; ↑ = prolonged or increased; ↑↑ = markedly prolonged; ↓ = decreased; PL = platelet count.
| Disorder | PT | aPTT | TT | BT | PL |
|---|---|---|---|---|---|
| Vitamin K deficiency / warfarin | ↑↑ | N or ↑ | N | N | N |
| Unfractionated heparin | N or ↑ | ↑↑ | ↑↑ | N | Usually N* |
| Liver disease | ↑ | N or ↑ | N or ↑ | Variable | N or ↓ |
| Haemophilia A or B | N | ↑ or ↑↑ | N | N | N |
| Qualitative platelet dysfunction | N | N | N | ↑ | Usually N |
| Von Willebrand disease | N | N or ↑ | N | Often ↑ | Usually N |
| DIC | ↑ | ↑ | N or ↑ | Often ↑ | ↓ |
| Immune thrombocytopenia (ITP) | N | N | N | Often ↑ | ↓ |
*Heparin-induced thrombocytopenia is a separate immune-mediated complication of heparin exposure. The table describes typical screening patterns; results vary with disease severity, reagent sensitivity and treatment. Bleeding time is an obsolete test and its values are shown only for historical examination comparison.
2. Understanding the Coagulation Tests
| Investigation | What It Assesses |
|---|---|
| PT / INR | Extrinsic and common pathways: factors VII, X, V, II and fibrinogen |
| aPTT | Intrinsic and common pathways: factors XII, XI, IX, VIII, X, V, II and fibrinogen |
| TT | Conversion of fibrinogen into fibrin |
| BT | Historical test of primary haemostasis and platelet function |
| Platelet count | Number of circulating platelets |
3. Coagulation Pathway Diagram
Simplified coagulation cascade showing the pathways assessed by PT, aPTT and TT.
4. Interpretation of Common Laboratory Patterns
A. Isolated Prolonged PT
Pattern: PT prolonged, aPTT normal.
Important causes include:
- Factor VII deficiency.
- Early vitamin K deficiency.
- Warfarin treatment.
- Early liver synthetic dysfunction.
B. Isolated Prolonged aPTT
Pattern: PT normal, aPTT prolonged.
Important causes include:
- Haemophilia A (factor VIII deficiency).
- Haemophilia B (factor IX deficiency).
- Factor XI deficiency.
- Unfractionated heparin.
- Lupus anticoagulant.
- Acquired coagulation factor inhibitors.
- Factor XII deficiency, which may prolong aPTT without causing a bleeding tendency.
C. Both PT and aPTT Prolonged
Important causes include:
- Disseminated intravascular coagulation.
- Severe liver disease.
- Severe vitamin K deficiency.
- Deficiencies affecting the common coagulation pathway.
- Some anticoagulant drug effects.
D. Normal PT and aPTT
Normal screening coagulation times do not exclude a bleeding disorder.
Important causes of bleeding with normal PT and aPTT include:
- Platelet dysfunction.
- Immune thrombocytopenia.
- Mild von Willebrand disease.
- Factor XIII deficiency.
- Vascular causes of bleeding.
5. Laboratory Interpretation Flowchart
Simplified interpretation guide. Confirm abnormal results and consider clinical history, medications, platelet count and additional testing.
6. Important Individual Disorders
A. Vitamin K Deficiency and Warfarin
Vitamin K is required for the production of functional coagulation factors II, VII, IX and X, as well as proteins C and S.
Factor VII has a relatively short half-life, so PT often becomes prolonged before aPTT.
- PT/INR: Prolonged.
- aPTT: Normal or prolonged, depending on severity.
- TT: Usually normal.
- Platelet count: Usually normal.
B. Unfractionated Heparin
Unfractionated heparin enhances the activity of antithrombin, increasing inhibition of thrombin and factor Xa.
- aPTT: Usually prolonged.
- TT: Prolonged.
- PT: May be normal or prolonged.
- Platelet count: Usually normal unless a complication such as heparin-induced thrombocytopenia develops.
C. Liver Disease
The liver synthesises most coagulation factors. Impaired hepatic synthetic function may prolong PT and aPTT.
- PT: Often prolonged.
- aPTT: May become prolonged in more advanced disease.
- TT: Normal or prolonged.
- Platelet count: May be reduced due to portal hypertension, splenic sequestration and other mechanisms.
Importantly, prolonged PT/INR in cirrhosis does not reliably predict spontaneous bleeding risk because both procoagulant and anticoagulant pathways are altered.
D. Haemophilia
Haemophilia A is caused by factor VIII deficiency, whereas haemophilia B is caused by factor IX deficiency.
- PT: Normal.
- aPTT: Often prolonged, especially in moderate or severe disease.
- TT: Normal.
- Platelet count: Normal.
Mild haemophilia may have a normal aPTT depending on assay sensitivity.
E. Platelet Disorders
Platelet disorders impair primary haemostasis and commonly cause mucocutaneous bleeding.
Typical clinical manifestations include petechiae, purpura, epistaxis and gingival bleeding.
PT and aPTT are generally normal. Platelet count is reduced in thrombocytopenia but may remain normal in qualitative platelet dysfunction.
F. Von Willebrand Disease
Von Willebrand factor supports platelet adhesion and stabilises circulating factor VIII.
- PT: Normal.
- aPTT: Normal or prolonged.
- TT: Normal.
- Platelet count: Usually normal.
- Platelet-dependent haemostasis: Impaired.
Diagnosis relies on appropriate von Willebrand factor antigen, activity and factor VIII testing rather than bleeding time.
G. Disseminated Intravascular Coagulation
DIC involves widespread activation of coagulation, with consumption of platelets and coagulation factors and secondary activation of fibrinolysis.
Typical laboratory findings include:
- Prolonged PT.
- Prolonged aPTT, although it may be normal early.
- Reduced platelet count.
- Elevated D-dimer or fibrin degradation products.
- Reduced or falling fibrinogen, although fibrinogen may initially be normal or increased.
- Possible prolonged thrombin time.
7. High-Yield Examination Summary
| Condition | Characteristic Finding |
|---|---|
| Haemophilia A/B | Isolated prolonged aPTT |
| Warfarin | Predominantly prolonged PT/INR |
| Unfractionated heparin | Prolonged aPTT and TT |
| Von Willebrand disease | Normal PT, normal or prolonged aPTT |
| ITP | Isolated thrombocytopenia |
| DIC | Thrombocytopenia, prolonged PT/aPTT, elevated D-dimer |
| Liver disease | Prolonged PT, sometimes prolonged aPTT and reduced platelets |
| Lupus anticoagulant | May prolong aPTT despite increased thrombosis risk |
8. Key Examination Pearls
- PT assesses the extrinsic and common coagulation pathways.
- aPTT assesses the intrinsic and common coagulation pathways.
- TT assesses the conversion of fibrinogen into fibrin.
- Haemophilia A and B typically cause prolonged aPTT with normal PT.
- Warfarin predominantly prolongs PT/INR.
- Unfractionated heparin prolongs aPTT and TT.
- Platelet disorders usually have normal PT and aPTT.
- Von Willebrand disease may have a normal or prolonged aPTT.
- DIC commonly causes thrombocytopenia, prolonged PT/aPTT and elevated D-dimer.
- Normal PT and aPTT do not exclude a clinically important bleeding disorder.
An isolated prolonged PT suggests an extrinsic pathway abnormality, while an isolated prolonged aPTT suggests an intrinsic pathway abnormality or inhibitor. Prolongation of both PT and aPTT suggests a common pathway defect, multiple factor deficiencies, DIC, severe liver disease or an anticoagulant effect.
Bleeding time is an outdated investigation and is not recommended for routine assessment of bleeding disorders. Modern evaluation uses platelet count, peripheral blood film, targeted coagulation factor assays, von Willebrand factor studies and platelet function testing when indicated. Screening results must always be interpreted alongside the patient's clinical history and medications.
Kembara Xtra – Medicine Revision Notes